Global Metabolic Disorder Drugs Market Briefing 2017 - Research and Markets
Wednesday, 03 January 2018 07:06
Jan. 3, 2018 17:54 UTC

Global Metabolic Disorder Drugs Market Briefing 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)-- The "Metabolic Disorder Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global metabolic disorder drugs market is expected to reach around $110 billion in 2020.

The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.

The market is expected to be driven by rapid growth in diabetic patients which, according to the World Health Organization, is expected to be the world's seventh leading cause of death in 2030.

Development Of New Anti-Diabetic Drugs For Type 2 Diabetes - Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment. Type 2 diabetes is a noninsulin-dependent diabetes that affects sugar (glucose) metabolism of the patient by either resisting or restricting the effects of insulin.

In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients. Similarly, in April 2017, scientists from the Central Drug Research Institute (CDRI) in India had found that chalcone, a plant-derived substance, can be used to produce an anti-diabetic drug that can improve insulin sensitivity and reduce blood glucose levels in patients with type-2 diabetes.

Scope:

  • Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and
    analysis throughout the report is sourced using end notes.

Companies Mentioned

  • Sanofi S.A.
  • Novo Nordisk A/S
  • AstraZeneca Plc.
  • Johnson & Johnson
  • Merck & Co.
  • Abbott Laboratories Inc.
  • Boehringer Ingelheim GmbH
  • AbbVie Inc.
  • Takeda Pharmaceuticals
  • Pfizer Inc.
  • Bayer AG

For more information about this report visit https://www.researchandmarkets.com/research/9gh8q6/global_metabolic?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs


Source: Research and Markets




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1